Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
Globenewswire· 2025-09-04 12:01
RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced that management will be participating in three upcoming Fall conferences. The Tharimmune team will present new results at the American College of Gastroenterology (ACG) Annual Scientific Meeting, being held October 24-29, 2025 at the Phoenix Convention Cente ...
EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening Its Stem Cell Therapy Portfolio
Globenewswire· 2025-09-04 12:00
Core Insights - EUDA Health Holdings Limited has secured distribution rights for T-cell immunotherapies in Malaysia from Shenzhen Inno Immune Co. Ltd, marking a significant expansion into advanced cell therapy [1][2] - The T-cell immunotherapy package will be priced at USD 8,000 per treatment, significantly lower than traditional costs in the region, making it more accessible [4] - This partnership is part of EUDA's strategy to diversify its healthcare portfolio and focus on regenerative and longevity medicine, addressing the healthcare needs of an aging population in Asia [5][6] Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to transform healthcare from reactive treatment to proactive, longevity-focused care [6] - The company aims to address the healthcare needs of over 1.8 billion people in the region, where more than 30% of the population is aging rapidly [6] - EUDA also operates a property management business in Singapore, further diversifying its operations [6] Strategic Partnerships - The agreement with Shenzhen Inno is facilitated by Guangdong Key Lock Health Management Co., Ltd, which has a long-term strategic partnership with both EUDA and Shenzhen Inno [3] - This partnership is expected to enhance EUDA's offerings in immune-enhancing therapies, leveraging Shenzhen Inno's scientific and institutional backing [5][8]
Emerita Resources Announces Increase to Loan Financing with Nebari Resources to Advance IBW Project
Globenewswire· 2025-09-04 12:00
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSXV: EMO) (the “Company” or “Emerita”) announces that it has entered into an amended credit agreement (the “Loan Agreement”) with Nebari Natural Resources Credit Fund II, LP (the “Lender” or “Nebari”) pursuant to which a fourth tranche of USD$35,000,000 will be m ...
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
Globenewswire· 2025-09-04 12:00
MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, and Catalent®, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, announced a strategic partnership redefining how investigational medicinal products (IMPs) are delivered directly to patients’ homes for clinical research. Through this collaboration, Catalent supports Science 37’s Direct-to-Patient Clinical Trial Site m ...
Roadzen Inc. Announces Strategic Equity Financing of Approximately $4.5 Million for Its India Subsidiary at an $84 Million Pre-Money Valuation
Globenewswire· 2025-09-04 12:00
Raise anchored by marquee investors, including leading family offices and institutional investors in India.Values Roadzen’s India Subsidiary, contributing less than 60% of global revenues, at approximately a 25% premium to the Nasdaq-listed parent company’s market capitalization.Proceeds are anticipated to accelerate India growth, drive technology acceleration for the global business, and reinforce Roadzen’s AI leadership – including DrivebuddyAI and core business lines – with 50%+ revenue CAGR expected for ...
BitFuFu Announces August 2025 Bitcoin Production and Operation Updates: Bitcoin Holdings Increasing to 1,899 BTC
Globenewswire· 2025-09-04 12:00
BitFuFu held 1,899 BTC as of August 31, 2025, an increase of 115 BTC from July 31, 2025.Self-owned hashrate grew 31.6% month-over-month to 5.0 EH/s, out of a total 35.6 EH/s under management.Average fleet efficiency improved to 17.5 J/TH. SINGAPORE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- BitFuFu Inc. (“BitFuFu” or the “Company”) (NASDAQ: FUFU), a world-leading Bitcoin miner and mining services innovator, today announced its unaudited production and mining operation updates for August 2025. “Our Bitcoin holdings ...
AgEagle Aerial Systems MicaSense Series RedEdge-P Multispectral Camera Available Now on Ascent’s SPIRIT™ and SPARTAN™ UAV Platforms
Globenewswire· 2025-09-04 12:00
Core Insights - AgEagle Aerial Systems Inc. has successfully integrated its MicaSense RedEdge-P multispectral camera with Ascent AeroSystems' SPIRIT and SPARTAN UAV platforms, enhancing capabilities in agricultural and environmental applications [1][2][3] Company Overview - AgEagle Aerial Systems Inc. is a global leader in drone technology, providing comprehensive solutions including drones, sensors, and software for various industries such as agriculture and public safety [7] - Ascent AeroSystems, founded in 2014, specializes in rugged, coaxial UAVs designed for defense, public safety, and industrial markets, emphasizing portability and durability [8] Product Features - The MicaSense RedEdge-P camera features five narrow multispectral bands and a high-resolution panchromatic imager, enabling precise vegetation data collection [2] - The SPIRIT and SPARTAN UAV platforms are designed with a cylindrical coaxial configuration, IP56-rated all-weather protection, and class-leading endurance, making them suitable for demanding missions [4] Market Context - The agricultural drone market is experiencing rapid growth, with increasing demand for reliable and high-performance platforms [5]
Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange
Globenewswire· 2025-09-04 12:00
GAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been selected to exhibit the EluPro™ Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange (“Vizient”). Vizient®, the nation’s largest provider-driven healthcare performance improvement company, will hold the Innovative Technology Exchange on Wednesday, September 17, 2025 in Las Vegas. The annual Inn ...
electroCore Partners with iHeartRadio and Former New York Jets Star Linebacker Greg Buttle to Champion Better Sleep and Stress Relief
Globenewswire· 2025-09-04 12:00
Core Insights - electroCore, Inc. has partnered with former NFL player Greg Buttle to promote its Truvaga™ Plus device, which is designed for vagus nerve stimulation to enhance relaxation, clarity, and sleep quality [1][4] - Truvaga Plus is a handheld device that utilizes bioelectronic technology to stimulate the vagus nerve, helping users transition from stress to a balanced state [3][8] - The partnership will include radio spots and digital campaigns aimed at raising awareness about stress management and the benefits of Truvaga Plus [4] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive technologies [6] - The company offers products like gammaCore and Quell, which treat chronic pain, alongside Truvaga and TAC-STIM for general wellness [6] - Truvaga Plus is backed by over 20 years of research in bioelectronic medicine and is intended for general health and wellness purposes [5][8]
ORYZON Finalist at the 2025 European Lifestars Awards
Globenewswire· 2025-09-04 12:00
Core Points - Oryzon Genomics has been selected as a Finalist in the 2025 European Lifestars Awards for the category Post-IPO Raise of the Year in the European Mediterranean region [1][2] - The nomination is attributed to the successful completion of a €30 million capital increase, which involved issuing 12.76 million new shares at €2.35 per share, reflecting a 15.44% discount to the 5-day volume-weighted average price and a 19.38% discount to the April 22, 2025 closing price [3] - The capital raise was significantly oversubscribed, with a U.S.-based institutional investor contributing €15 million, and additional participation from investors across the U.S., Europe, and Spain [3] Company Overview - Oryzon Genomics, founded in 2000 in Barcelona, Spain, is a clinical-stage biopharmaceutical company specializing in epigenetics and personalized medicine, particularly in CNS disorders and oncology [5] - The company has an advanced clinical portfolio that includes two LSD1 inhibitors, vafidemstat (Phase III-ready) and iadademstat (Phase II), along with other pipeline assets targeting various epigenetic mechanisms [5] - Oryzon has established a strong platform for biomarker identification and target validation for a range of malignant and neurological diseases [5]